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MAG13–AKT3 fusion in breast cancer amended 
ARISING FROM S. Banerji et al. Nature 486, 405–409 (2012) 
Banerji et al.1 described a novel MAGI3–AKT3 rearrangement in breast cancer, enriched in triple 
negative tumours. The report was highly encouraging as targeted therapies could potentially 
serve as a new and much needed option to treat this highly aggressive breast cancer subtype. We 
sought to confirm the presence of this rearrangement in 236 samples of triple negative breast 
cancer (TNBC) by using fluorescent in situ hybridization (FISH) and reverse transcription-
polymerase chain reaction (RT–PCR), and in 84 additional cases from The Cancer Genome Atlas 
by using FusionSeq. No evidence of the fusion was found in any of the tumours studied. Our 
study confirms that MAGI3–AKT3 fusion is not a recurrent event in triple negative breast cancer, 
which should be acknowledged before considering the evaluation of targeted therapies in clinical 
trials. There is a Reply to this Brief Communication Arising by Pugh T. et al. Nature 520, 
http://dx.doi.org/10.1038/nature14266 (2015). 
TNBC constitutes the majority of breast carcinomas of the basal-like molecular subtype, 
and is defined by absence of actionable therapeutic targets (ER, PR, HER-2). TNBC patients 
have a poor response to conventional breast cancer therapies2 and experience poor survival3. As 
such, molecular elucidation of these tumours is critical in the hopes of developing novel targeted 
therapies4. 
Discovery of functionally recurrent gene rearrangements is a relatively new avenue in 
breast cancer (for example, MAST kinase and Notch gene families5). Banerji et al. reported a 
MAGI3–AKT3 gene fusion to be present in 7% (5/72) of TNBC1. This balanced translocation 
results in a constitutive activation of AKT kinase, which can be countered using small molecule 
AKT inhibitors. 
We aimed to determine the frequency of MAGI3–AKT3 fusion in 236 TNBCs represented 
in high-density tissue microarrays (see Table 1). Following previously described protocols6–8, 
FISH was performed using dual colour locus-specific probes for MAGI3 and AKT3. None of the 
cases showed either MAGI3 or AKT3 break-apart or fusion signals. To exclude the possibility of 
intra-tumour heterogeneity, multiple regions of full tumour sections were screened in a subset of 
28 cases, all of which were also negative for break-apart and fusion signals (see Fig. 1). 
Additionally, shorter primer sequences were designed to test a 187 bp fusion product of intron 9 
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of MAGI3 with intron 1 of AKT3 in archival material. We performed RT–PCR of cDNA in 135 
of these cases. No MAGI3–AKT3 fusion product was detected. Further, we investigated RNA-seq 
data from 84 TNBC cases from The Cancer Genome Atlas with FusionSeq9. We did not find any 
evidence of MAGI3–AKT3 gene fusion in these cases either. 
Our sample size has sufficient power to detect with 95% confidence gene rearrangements 
that would occur at a frequency of as low as 3%. Based on our results, we can reliably conclude 
that MAGI3–AKT3 rearrangement is neither recurrent nor sub-clonal in TNBC. To assume that 
MAGI3–AKT3 fusion was a recurrent event in TNBC, Banerji et al.1 interrogated their tumours 
by using RT–PCR of cDNA followed by Sanger sequencing only. Confirmation at the genomic 
level by PCR of genomic DNA was performed exclusively in the index case. Hence, we favour 
that, with the exception of the index case, the sequenced RT–PCR products by Banerji et al.1 
represent a post-transcriptional fusion event (trans-splicing), rather than a true genomic event. 
Our patient cohort of mainly Caucasian women in contrast to those of Mexican and 
Vietnamese decent studied in Banerji et al.1 raises the possibility that this rearrangement may be 
population-enriched, a prospect that needs further study. 
Methods 
Locus specific probes were located at 1p (MAGI3: BAC 5ʹ′ RP11-1133G15 and 3ʹ′ RP11-1008I9) 
and 1q (AKT3: BAC 5ʹ′ RP11-931B5 and 3ʹ′ RP11-989N14). At least 150 nuclei per case were 
interrogated in tissue microarrays. In full sections, ~2,000 nuclei per slide were evaluated. 
FusionSeq9 is a robust computational tool to detect fusion transcripts in paired-end RNA-seq 
data10–12. Reads were aligned to the human reference genome sequence (GRC37/hg19) using 
STAR13. PCR primers sequences are as follows. MAGI3 forward: 5ʹ′-
TGTCCTTGTTCGAGCATCAC-3ʹ′, MAGI3 reverse: 5ʹ′-GAGGACACAGTTGCCATTGA-3ʹ′, 
AKT3 forward: 5ʹ′-TGAAAGAAGGTTGGGTTCAGA-3ʹ′, AKT3 reverse: 5ʹ′-
GCCACTGAAAAGTTGTTGAGG-3ʹ′. PGK was used as control gene. 
Figure 1 Absence of MAGI3–AKT3 fusion in triple negative breast cancer. a, Haematoxylin and 
eosin (H & E) stained full section of a representative case of triple-negative breast cancer. b, c, 
Tissue microarrays (b) and multiple regions of the entire section (c) were interrogated by FISH 
(total of 236 cases). d, No break-apart signals for MAGI3 or AKT 3 were identified. No MAGI3-
AKT3 fusion product was detected by RT–PCR in a subset of 135 cases. 
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Table 1: Clinico-pathologic characteristics of 236 triple negative breast cancers 
Patient Age 22–92 years  
   
Tumour size 0.3–7.4 cm  
 
Number of tumour type cases† 
 
Invasive ductal carcinoma 
 
218* 
 Invasive lobular carcinoma 5 
 Metaplastic carcinoma 5 
 Other 8 
 
Stage (percentage of cases) 
 
Stage IA 
 
47.1% 
 Stage IB 0.6% 
 Stage IC 0.6% 
 Stage IIA 31.4% 
 Stage IIB 6.5% 
 Stage IIIA 4.6% 
 Stage IIIB 2.0% 
 Stage IIIC 4.0% 
 Stage IV 2.6% 
 Not available  0.6% 
 
Ki-67 (proliferation index 
 
High (≥ 10%) 
 
219 cases 
 Low (< 10%) 17 
Weill Cornell cohort (n = 153) and University Hospital Zürich cohort (n = 83) 
†Includes 6 cases from recurrence or metastases, as follows: 1 case of chest wall recurrence; 3 cases of 
ipsilateral lymph node metastases, 1 case of upper arm metastasis, 1 case of femoral metastasis (Weill 
Cornell cohort)  
*Includes two patients who had bilateral tumours (Weill Cornell cohort). 
 
Juan-Miguel Mosquera1,2*, Sonal Varma1*, Chantal Pauli1,2,3, Theresa. Y. MacDonald1, Jossie J. Yashinskie1, 
Zsuzsanna Varga3, Andrea Sboner1,2,4, Holger Moch3, Mark. A. Rubin1,2§ & Sandra. J. Shin1§ 
1Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York, 10065 
USA. 
2Institute for Precision Medicine of Weill Cornell Medical College and New York-Presbyterian Hospital, New York, 
New York 10021, USA. 
3Institute for Surgical Pathology, University Hospital Zürich 8091, Switzerland. 
4Institute for Computational Biomedicine, Weill Cornell Medical College, New York, New York 10021, USA. 
email: rubinma@med.cornell.edu 
*These authors contributed equally to this work. 
§These authors jointly supervised this work. 
Received 17 March 2013; accepted 9 January 2015 
Competing Financial Interests: Declared none. 
<jrn>1. Banerji, S. et al. Sequence analysis of mutations and translocations across breast cancer 
subtypes. Nature 486, 405–409 (2012). Medline CrossRef</jrn> 
Publisher: NPG; Journal: Nature: Nature; Article Type: BCA 
 DOI: 10.1038/nature14265 
Page 4 of 5 
<jrn>2. Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A. & Caggiano, V. Descriptive 
analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and 
HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a 
population-based study from the California cancer Registry. Cancer 109, 1721–1728 
(2007). Medline CrossRef</jrn> 
<jrn>3. Pal, S. K., Childs, B. H. & Pegram, M. Triple negative breast cancer: unmet medical 
needs. Breast Cancer Res. Treat. 125, 627–636 (2011). Medline CrossRef</jrn> 
<jrn>4. Craig, D. W. et al. Genome and transcriptome sequencing in prospective refractory 
metastatic triple negative breast cancer uncovers therapeutic vulnerabilities. Mol. Cancer 
Ther. 12, 104–116 (2013). Medline</jrn> 
<jrn>5. Robinson, D. R. et al. Functionally recurrent rearrangements of the MAST kinase and 
Notch gene families in breast cancer. Nature Med. 17, 1646–1651 (2011). Medline 
CrossRef</jrn> 
<jrn>6. Berger, M. F. et al. The genomic complexity of primary human prostate cancer. Nature 
470, 214–220 (2011). Medline CrossRef</jrn> 
<jrn>7. Perner, S. et al. TMPRSS2:ERG fusion-associated deletions provide insight into the 
heterogeneity of prostate cancer. Cancer Res. 66, 8337–8341 (2006). Medline 
CrossRef</jrn> 
<jrn>8. Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes 
in prostate cancer. Science 310, 644–648 (2005). Medline CrossRef</jrn> 
<jrn>9. Sboner, A. et al. FusionSeq: a modular framework for finding gene fusions by analyzing 
paired-end RNA-sequencing data. Genome Biol. 11, R104 (2010). Medline 
CrossRef</jrn> 
<jrn>10. Pflueger, D. et al. Discovery of non-ETS gene fusions in human prostate cancer 
using next-generation RNA sequencing. Genome Res. 21, 56–67 (2011). Medline 
CrossRef</jrn> 
<jrn>11. Mosquera, J. M. et al. Recurrent NCOA2 gene rearrangements in 
congenital/infantile spindle cell rhabdomyosarcoma. Genes Chromosom. Cancer 52, 
538–550 (2013). Medline CrossRef</jrn> 
Publisher: NPG; Journal: Nature: Nature; Article Type: BCA 
 DOI: 10.1038/nature14265 
Page 5 of 5 
<jrn>12. Mosquera, J. M. et al. Novel miR143-NOTCH fusions in benign and malignant 
glomus tumors. Genes Chromosom. Cancer 52, 1075–1087 (2013). Medline 
CrossRef</jrn> 
<jrn>13. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 
15–21 (2013). Medline CrossRef</jrn> 
Author Contributions J.M.M. performed experimental work and wrote paper; S.V. performed experimental work 
and wrote paper; C.P., T.Y.M., J.J.Y., Z.V. and H. M. performed experimental work; A.S. performed data analysis; 
S.J.S. performed project planning and revised paper; M.A.R. designed research, performed project planning and 
revised paper. 
Competing Financial Interests Declared none.  
 
MAGI3 AKT3
a b
d
c
